ACT Signature Webinars

Approach to Development of an Inhalation Excipient for Regulatory Approval: Case Studies with HFA-152a and DSPC 

03-22-2023 03:02 PM

Hosted by the American College of Toxicology.
With support from the British Toxicology Society and the Society of Toxicologic Pathology.

Philip J. Kuehl, PhD, Lovelace Biomedical
Jake McDonald, PhD, Lovelace Biomedical

The purpose of this webinar is to define the requirements for regulatory development of excipients used in respiratory formulations. As a part of the regulatory development pathway, pharmacology, toxicology, and clinical studies are conducted. These studies require specialized approaches to determination of maximum feasible dose, determination of drug absorption/pharmacokinetics, and design of the toxicology programs. This webinar will describe the approach for the technical and regulatory approval, utilizing two case studies that involve excipients of broad importance to respiratory therapy and represent pressurized meter dose inhalers [1,1-Difluoroethane (HFA-152a)] and dry powder excipients [phosphatidylcholine (PC), 1,2-distearoyl-sn-glycero-3-phosphocholin, DSPC)]. The regulatory discussion will consider both US and international requirements. The webinar will include an overall approach and technical details that include system characterization (in vitro, rodent, canine, human), analytical and bioanalytical assessment, pharmacokinetics, and toxicology including dose range finding, safety pharmacology, carcinogenicity, IND, and NDA studies.

View Webinar Recordings

Webinar materials are property of the speaker and the American College of Toxicology and are intended for use by the host society and co-host societies' members for educational purposes only. Any distribution or copy of the materials is prohibited. By downloading from the link provided you agree to the terms expressed above.

0 Favorited
1 Files
pdf file
ACT_Webinar_March8.pdf   2.59 MB   1 version
Uploaded - 03-23-2023

Related Entries and Links

No Related Resource entered.